TPTX Stock Performance, Insider Transaction and News

TPTX - Turning Point Therapeutics, Inc

Market Cap	3.81B	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-342.31M	Forward P/E	-10.54	EPS next Y	-	50D Avg Chg	1.00%
Sales	1.01M	PEG	-	EPS past 5Y	-	200D Avg Chg	63.00%
Dividend	N/A	Price/Book	4.78	EPS next 5Y	-	52W High Chg	-8.00%
Recommedations	3.00	Quick Ratio	16.56	Shares Outstanding	50.07M	52W Low Chg	220.00%
Insider Own	0.70%	ROA	-22.13%	Shares Float	48.20M	Beta	-0.19
Inst Own	92.52%	ROE	-36.80%	Shares Shorted/Prior	2.14M/2.86M	Price	76.01
Gross Margin	100.00%	Profit Margin	-	Avg. Volume	1,897,877	Target Price	71.50
Oper. Margin	-34,185.81%	Earnings Date	Nov 7	Volume	2,843,392	Change	0.00%

Healthcare | Biotechnology | United States

About Turning Point Therapeutics, Inc

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

TPTX Chatroom

NVDAMillionaire Posted - 2 months ago

$TPTX Turning Point Therapeutics, Inc. (NASDAQ:TPTX): A Promising Precision Oncology Company Navigating Clinical Trials and Regulatory Milestones http://beyondspx.com/2024/08/05/turning-point-therapeutics-inc-nasdaqtptx-a-promising-precision-oncology-company-navigating-clinical-trials-and-regulatory-milestones/

Auphiliate Posted - 03/28/24

@Maxwell_Smart I’m far from being an expert…. That said, I’m also in $TPTX for trial results this fall, $TGTX for increase within ~ 1.5 years due to their partnership clause which allows a bo within two years (now ~ 1.5), and tiny stake in $EPIX. Watching a couple of others. Stuck with a few thousand shares in $SRNE and $SCLX, awaiting results of CH11 🤦‍♀️. My 401K is in biotechnology and oil( energy) mutual funds. Rec’d a very small amt. of bitcoin for Christmas from my millionnaire bitcoin son and will cost average there, over time! Wish me luck—and you too! 😊

Quantumup Posted - 03/27/24

Jefferies⬆️ $NUVB Buy/$10 was Hold/$1.4 =$3B valuation or 300% upside/not a stretch if pivotal P2B ROS1 lung cancer data is confirmed this yr/early data looks as good as $NUVL/ $TPTX which are $4-5B valuations. This is an under-followed small cap w/ new story w/ this new Tx. $bmy

kubota2323 Posted - 03/22/24

$MAIA hopefully can turn into $TPTX in time.

Oncinvestor Posted - 9 months ago

@junkiegite @markovb343 @sulljd74 $tptx doesn’t have as good of a ROS1 inhibitor as $nuvl and $nuvl will leap frog lorlatinib in ALK and eventually alectinib S well because of its side effect profile. Wouldn’t be surprised to see a buy out in the next two years pending data

TrendyChart Posted - 1 year ago

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/17/2023 at 4:00PM | Are you looking for a positive or negative earnings outcome?

TrendyChart Posted - 1 year ago

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/17/2023 at 4:00PM | Do you have a rosy or gloomy earnings perspective for this stock?

TrendyChart Posted - 10/31/23

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/10/2023 at 4:00PM | What's your take on the earnings potential of this stock?

TrendyChart Posted - 10/31/23

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/10/2023 at 4:00PM | Are you leaning towards a positive or negative earnings forecast?

Oncinvestor Posted - 1 year ago

@illdefinedmind patients being treated with reprotrectinib are already having to switch to $NUVL’s inhibitor because of mutations (porter discussed this at recent conferences). ALK is a much bigger market with lots of room for improvements. I take alectinib as an ALK pos patient but many of my friends find lorlatinib side effects to be brutal. $tptx had an alk inhibitor too but it was too toxic.

Oncinvestor Posted - 1 year ago

@illdefinedmind $BMY bought $TPTX for $4 billion plus on ROS1 data alone. Big companies will want these drugs before they are approved.

mackinvestor Posted - 1 year ago

$BPMC Not worried about $BPMC Swings in $BPMC can be wild From 59 on June 3, 2022 (day of $BMY $TPTX buyout) to 45 on June 14 & 60 on June 24 Wish management would do something "transformative" to take control away from algos, MM's, Citadel Securities, etc.

Nostradamus696 Posted - 04/25/23

$SGEN $TPTX $SRRA $MYOV. Altimmune smells like a buyout too. I would know 😉

risenhoover Posted - 03/26/23

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/25/23

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/24/23

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/23/23

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/22/23

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget